Loading...
Loading...
Browse all stories on DeepNewz
VisitWill Wave Life Sciences stock increase by 20% or more by December 31, 2024?
Yes • 50%
No • 50%
Stock market data from financial platforms like Bloomberg or Yahoo Finance
Takeda Ends Six-Year $260M Collaboration with Wave Life Sciences on Mutant Huntingtin-Specific ASO
Oct 16, 2024, 08:55 AM
Takeda Pharmaceutical Company, a Japanese pharma, has decided to terminate its option for the mutant huntingtin-specific ASO target in its collaboration with Wave Life Sciences. This decision marks the end of a six-year partnership into which Takeda had invested $260 million. The collaboration was focused on developing treatments for Huntington's disease.
View original story
Yes • 50%
No • 50%
0-10% • 25%
11-20% • 25%
21-30% • 25%
Above 30% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Huntington's Disease • 25%
Other • 25%
Duchenne Muscular Dystrophy • 25%
ALS • 25%
Other • 25%
Neurological Disorders • 25%
Genetic Diseases • 25%
Oncology • 25%